Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conferenceseries Ltd: World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Previous Speakers

Judith Miller

Judith Miller

International Neural Renewal Center USA

Rebecca Cooper

Rebecca Cooper

Member of International Association of Eating Disorder Professions USA

Jeff Zacharias

Jeff Zacharias

New Hope Recovery Center USA

Frank Galimidi

Frank Galimidi

New Beginnings Recovery Center USA

Konstantin Slavin

Konstantin Slavin

University of Illinois USA

Durodami Lisk

Durodami Lisk

Ministry of Health USA

Peter Kaplan

Peter Kaplan

Johns Hopkins University USA

Michael Sofroniew

Michael Sofroniew

Department of Neurobiology UCLA School of Medicine USA

Dementia 2018

Sessions/Tracks

 

Track 1: Alzheimer’s disease Diagnosis and Symptoms

Alzheimer's is caused by brain cell death. It is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. The total size of the brain shrinks in Alzheimer's, nerve cells and connections in the tissue progressively reduced, which cannot be seen or tested in the living brain affected by Alzheimer's disease, post-mortem/autopsy will always show tiny inclusions in the nerve tissues, called as plaques and tangles. Plaques are found between the dying cells in the brain - from the build-up of a protein called beta-amyloid (amyloid plaques). The tangles exist in the brain neurons, from a disintegration of second protein, called tau.

Worldwide, with Dementia or Related disorders nearly 44 million people have suffered in 2015,past results shown 35.66 million population  lived with dementia  worldwide in year 2010, with numbers expected to nearly double each twenty years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, fifty-eight per cent of all population with dementia lived in countries with lower or moderate incomes, with this proportion anticipated to rise to 63% till 2030 and 71% by 2050. This condition is anticipated to double by 2030 and quite triple by 2050 to 115 million.

In this track we can discuss on Neurological changes in brain, Amyloid protein, Genetic associations and susceptibility genes, Role of Apo lipoprotein E, Brain trauma, Metabolic syndrome and Alzheimer’s disease, Protein misfolding, aggregation and toxicity, Disease-causing mutations, Epidemiology and prevalence, Histone modification, DNA methylation, Alzheimer’s disease prevention.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 2: Managing Dementia

Dementia is the term used to describe the symptoms of several conditions that affecting the brain. The commonly seen condition is Alzheimer’s, and other includes Parkinson's disease. Symptoms seen at early stages are personality changes, withdrawal, memory loss, confusion and apathy. Early diagnosis helps with providing early treatment, support and planning. Medications might help with some symptoms of dementia, but no permanent cure.

Majority of people with dementia are above age 65, the condition is not normal for all older people. The occurrence of dementia gets high with age, but it’s not given that an older person will develop it. While only 1-in-4 people with Alzheimer’s disease or Dementia has been diagnosed. Few more things we need to know about vascular dementia, Dementia with lewy bodies, Fronto-temporal dementia, Rarer causes of dementia, Creutzfeldt-Jakob disease, HIV-related cognitive impairment, Mild cognitive impairment.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Persons with dementia have multiple psychological feature deficits that include each memory impairment, that affects the flexibility to find out new info or recall information previously learned, and one or additional of the subsequent symptoms-aphasia, apraxia, agnosia, or executive dysfunction-such that the psychological feature deficits negatively have an effect on social or activity functioning with a big decline in previous talents. Additionally, persons with dementia typically suffer from comorbid conditions that additional complicate care and impede best outcomes. Therefore, developing caregiving methods people with dementia is urgent, given this increasing prevalence and therefore the associated burden that dementia places not only on the individuals, however on the caregivers, relations, and therefore the resources of the health care system. Conventional views bearing on geriatric nursing typically paint an image of the care as being slow paced certain and less demanding than acute care. However, care of the aged, and particularly those with dementia, is usually complicated, unpredictable, and unstable.

This session includes Education and training of medical professionals, Care and quality of life, Person centered care, Cognitive training, Support and training for informal and professional careers, Putting scientific knowledge into practice, Non-pharmacological Interventions, Functional foods, Art, music and life style.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 4: Alzheimer’s disease Imaging

Scientists look at the brain’s grey matter when investigating about Alzheimer’s disease. A fresh study, found that degenerating white matter in the brain could be an early indicator of disease. A study was published in Radiology which concludes that white matter plays an important role in how the disease strikes and progresses. Abnormal deposits of proteins that form amyloid plaques and tau tangles all over the brain in Alzheimer’s disease. It can also be characterized by shrinkage of brain tissues due to neurons loss.

This session includes Amyloid and Tau imaging, Imaging animal models, Imaging and genetics, New methods in imaging, Structural and functional MRI, Positron emission tomography, MR spectroscopy, EEG and brain mapping, SPECT imaging, Imaging correlates of clinical, cognitive and biomarker variables.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 5: Causes and Prevention of Alzheimer’s

Alzheimer's is caused by brain cell death. It is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. The total size of the brain shrinks in Alzheimer's, nerve cells and connections in the tissue progressively reduced, which cannot be seen or tested in the living brain affected by Alzheimer's disease, post-mortem/autopsy will always show tiny inclusions in the nerve tissues, called as plaques and tangles. Plaques are found between the dying cells in the brain - from the build-up of a protein called beta-amyloid (amyloid plaques). The tangles exist in the brain neurons, from a disintegration of second protein, called tau.

Worldwide, with Dementia or Related disorders nearly 44 million people have suffered in 2015, past results shown 35.66 million population  lived with dementia  worldwide in year 2010, with numbers expected to nearly double each twenty years, to 65.7 million in 2030 and 115.4 million in 2050. In 2010, fifty-eight per cent of all population with dementia lived in countries with lower or moderate incomes, with this proportion anticipated to rise to 63% till 2030 and 71% by 2050. This condition is anticipated to double by 2030 and quite triple by 2050 to 115 million.

In this track we can discuss on Neurological changes in brain, Amyloid protein, Genetic associations and susceptibility genes, Role of Apo lipoprotein E, Brain trauma, Metabolic syndrome and Alzheimer’s disease, Protein misfolding, aggregation and toxicity, Disease-causing mutations, Epidemiology and prevalence, Histone modification, DNA methylation, Alzheimer’s disease prevention.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 6: Alzheimer’s disease Pathophysiology and Disease Mechanisms

Alzheimer’s disease is a progressive dementia with loss of neurons and the presence of two main microscopic neuropathological hallmarks: extracellular amyloid plaques and intracellular neurofibrillary tangles. Early onset AD, a rare familial form, is caused due to mutation of one out of three genes: (amyloid precursor protein), (presenilin 2) or (presenilin 1).  Sporadic form occurs usually after age of 65 and accounts for most cases; it most likely results from a combination of genetic and influence of environment. Confirmed risk factors for sporadic AD are age and the presence of the E4 allele of (Apo lipoprotein E). Amyloid plaques comprise mainly of the neurotoxic peptide amyloid (Aβ, Abeta), cleaved sequentially from a larger precursor protein (APP) by two enzymes: β-secretase (also called BACE1) and γ-secretase (comprising four proteins, presenilin is one of them). If APP is first cleaved by the enzyme α-secretase rather than β-secretase then Aβ is not formed. Neurofibrillary tangles comprise mainly of the protein tau which binds with microtubules, which facilitating the neuronal transport system. Tau uncoupling from microtubules and aggregation into tangles inhibits transport and results in disassembly of microtubule. Phosphorylation of tau might have an important role in this. Selective vulnerability of neuronal systems such as the cholinergic, serotonergic, and noradrenergic and glutamatergic systems form the basis of current rational pharmacological treatment.

This session includes Aging, Prions and Alzheimer’s disease, Cellular signaling and cell to cell transmission, Oxidative damage and mitochondrial dysfunction, Autoimmunity in Alzheimer’s, Blood-brain barrier and transport, Neurogenesis and stem cells and Cell death.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 7: Amyloid Protein in Alzheimer’s and Dementia

The amyloid plaques and neurofibrillary tangles formation are thought to contribute to the degradation of the neurons (nerve cells) in the brain and the subsequent symptoms of Alzheimer's disease.

Amyloid Plaques: One of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in brain. Amyloid generally indicates protein fragments that the body produces normally. Beta amyloid is a protein fragment from an amyloid precursor protein (APP). In a healthy brain, these protein fragments are broken down and get eliminated. In Alzheimer’s, the fragments get accumulated to form hard &insoluble plaques.

Neurofibrillary Tangles: Neurofibrillary tangles are insoluble twisted fibers found inside the brain's cells, consisting primarily of a protein called tau, which forms structure called a microtubule. Transport of nutrients and other important substances from one part of the nerve cell to another done by help of microtubule. In Alzheimer's disease, the tau protein is abnormal and results in collapse of the microtubule structures.

This session includes Amyloid Protein and Alzheimer’s Disease, Amyloid beta metabolism in Alzheimer’s, Brain accumulation of toxic amyloid beta, Amyloid Plaques and Neurofibrillary Tangles, Amyloid Neuroimaging and biomarkers, Amyloidosis and Neurodegeneration, The amyloid hypothesis and potential treatments, Amyloid beta deposition, cognition and brain volume.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 8: Geriatrics Dementia and Cognitive Disorder

Geriatrics or geriatric medication may be a specialty that focuses on health care of older people. It aims to push health by preventing and treating diseases and disabilities in older adults. there's no set age at that patients are also underneath the care of a specialist or geriatric MD; a MD United Nations agency makes a specialty of the care of older people. Rather, this call is set by the individual patient’s needs, and therefore the availableness of a specialist. It’s vital to notice the distinction between gerontology, the care of aged people, and geriatrics, that is that the study of the aging method itself.

Cognitive disorders square measure a class of mental state disorders that primarily influence learning, memory, perception, and drawback determination, and embody blackout, dementia, and delirium. Whereas anxiety disorders, mood disorders, and psychotic disorders can even have an effect on psychological feature and memory functions, the DSM-IV-TR doesn't contemplate these psychological feature disorders, because loss of cognitive function is not the primary (causal) symptom. Causes vary between the various sorts of disorders however most include damage to the memory parts of the brain. Treatments rely on however the disorder is caused. Medication and therapies square measure the foremost common treatments but, for a few sorts of disorders like amnesia, treatments will suppress the symptoms however there is presently no cure.

This session includes Neurodegenerative diseases, Geriatric emergency medicine, Geriatric diagnostics, Geriatric neurology, Geriatric oncology, Geriatric psychiatry or psychogeriatric, Geriatric pharmacotherapy, Alcohol addiction and mental health, Nutritional deficiency, Preventions: Mental activity and healthy lifestyle.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 9: Therapeutic Targets and Mechanisms for Treatment

Alzheimer's disease is a progressive neurodegenerative disease that is characterized histopathologically by the presence of plaques, mainly composed of Abeta amyloid and the tangles, mainly composed of hyper phosphorylated tau. To date, there is no treatment that can reverse the disease, and all the current therapeutics is directed to cope with the symptoms of the disease. Here we describe the efforts dedicated to attack the plaques and, in more detail, the process of neurofibrillary degeneration, linked to the presence of the hyper phosphorylated microtubule associated protein tau. We have identified the different putative targets for therapeutics and the current knowledge on them.

Treatment for Alzheimer's disease is entering a new and exciting phase, with several new drugs beginning clinical trials. Many of these new therapies are based on our best current understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease. There are several different theories underlying the current efforts, and these are briefly reviewed. Therapies directed against some aspect of beta-amyloid formation, against neurofibrillary tangle formation and against the inflammatory response are all considered, as are the problems associated with each area. It is yet unclear which, if any of these approaches will be successful, but the high level of activity in each of these three fields provides some hope that an effective treatment for Alzheimer's disease is on the horizon.

This session includes Abeta, truncated and pGlu-Abeta, Immunotherapy, Neurotransmitter-based targets, Anti-inflammatory targets, Nanotechnology, Anti-oxidants, Neurotrophic factors, Protein aggregation, Deep brain stimulation, Misfolding and chaperones, Gene therapy, Drug-delivery systems.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 10: Animal Models and Translational Medicine

Animal models for Alzheimer’s disease it is important to think about the human phenotype and what is being modeled in terms of the animal phenotype. The moderator, Bradley Hyman, professor of neurology at Harvard Medical School, said that animal models of Alzheimer’s disease, based on the genetics of the disease and the closely related frontotemporal dementia, replicate at least some of the pathology. Researchers have been successful at modeling very specific aspects of Alzheimer’s disease in the mouse (e.g., plaques, tangles). Although these are incomplete models of the human disease, they have been well received in the field as potentially relevant models for use in drug discovery.

Patients with Alzheimer’s disease will display both amyloidopathy and tauopathy; however, scientists often focus, in a reductionist way, on one or the other in an animal model. A participant added that even though the anatomy in the mouse is different than the human, mutant tau mice are relatively good models in that they recapitulate tau-dependent neurodegeneration. This has led many companies to focus on antibodies that block tau-dependent neurodegeneration in these mouse models.

This session includes Transgenic models, Pharmacological and lesion models, Natural and semi natural models, Primate models, Zebra fish models, Animal models of human cognitive aging, Development of new animal models, Genetics of translational models, Protein-protein interactions, Ethical issues with animal models.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 11: Vascular Dementia

Vascular dementia, otherwise called multi-infarct dementia is the second most basic reason for dementia in more seasoned individuals. Since it has a lower profile than Alzheimer's, many individuals don't speculate vascular dementia when neglect ends up noticeably hazardous. It's additionally hard to analyze so it's hard to know precisely what number of individuals experience the ill effects of vascular dementia. Current evaluations credit 15% to 20% of dementia cases in more established grown-ups to vascular dementia. Vascular dementia happens when vessels that supply blood to the cerebrum wind up noticeably blocked or limited. Strokes happen when the supply of blood conveying oxygen to the mind is suddenly cut off. Be that as it may, not all individuals with stroke will create vascular dementia. Vascular dementia can happen after some time as "noiseless" strokes heap up. Frequently, vascular dementia attracts regard for itself just when the effect of such many strokes means noteworthy handicap. Staying away from and controlling danger factors, for example, diabetes, hypertension, smoking, and elevated cholesterol can help check the danger of vascular dementia.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 12: Alzheimer’s disease and Dementia

Alzheimer's is the most well-known type of dementia, a general term for memory misfortune and other psychological capacities sufficiently genuine to meddle with day by day life. Alzheimer's infection represents 60 to 80 percent of dementia cases.

Alzheimer's isn't a typical piece of maturing. The best-known hazard factor is expanding age, and the dominant part of individuals with Alzheimer's are 65 and more seasoned. Be that as it may, Alzheimer's isn't only an illness of maturity. Around 200,000 Americans younger than 65 have more youthful beginning Alzheimer's ailment (otherwise called early-beginning Alzheimer's). Alzheimer's has no ebb and flow cure, yet medicines for side effects are accessible and consider proceeds. Albeit current Alzheimer's medicines can't prevent Alzheimer's from advancing, they can incidentally moderate the compounding of dementia manifestations and enhance personal satisfaction for those with Alzheimer's and their parental figures. Today, there is an overall exertion under approach to discover better approaches to treat the illness, postpone its beginning, and keep it from creating.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 13: Traumatic brain injury

Traumatic brain injury (TBI) is unpredictable damage with a wide range of side effects and incapacities. The effect on a man and his or her family can demolish. The reason for this site is to teach and enable guardians and survivors of awful mind wounds. This site expects to facilitate the progress from stun and lose hope at the season of cerebrum damage to adapting and critical thinking.

The side effects of mind wounds and the country's best awful cerebrum damage recovery focuses and asset data.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 14: Dementia with Lewy Bodies

Lewy bodies are likewise found in other cerebrum issue, including Alzheimer's malady and Parkinson's illness dementia. Many individuals with Parkinson's in the end create issues with considering and thinking, and many individuals with DLB encounter development manifestations, for example, slouched pose, inflexible muscles, a rearranging walk and inconvenience starting development.

Indications of dementia with Lewy bodies include:

Changes in considering and thinking

·         Perplexity and readiness that differs fundamentally starting with one time of day then onto the next or starting with one day then onto the next.

·         Parkinson's indications, for example, a slouched pose, adjust issues and inflexible muscles.

·         Visual mental trips.

·         Hallucinations.

·         Glitches of the "programmed" (autonomic) sensory system.

·         Memory misfortune that might be critical however less unmistakable than in Alzheimer's.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

Track 15: Alzheimer’s clinical trials and studies

Clinical trials are inquired about examinations led in individuals to decide if medicines are protected and viable. Without clinical research and the assistance of human volunteers, there can be no better medications, no counteractive action and no cure for Alzheimer's ailment.

Clinical trials are occasionally alluded to as clinical examinations; the terms are frequently utilized reciprocally, yet there are unobtrusive contrasts between them. Clinical trials test new intercessions or medications to avoid, recognize or treat infection. A clinical report is any sort of clinical research including individuals, paying little heed to whether it is trying an intercession. Clinical examinations can likewise take a gander at different parts of care, for example, enhancing personal satisfaction.

Related Dementia Conferences | Alzheimer’s conferences | Dementia Meetings | Neuroscience Conferences

21st World Congress on Neurology and Therapeutics, March 15-17, 2018 London, UK; 22nd International Conference on Neurology & Neurophysiology, April 23-24, 2018 Rome, Italy; 23rd International Conference on Neurology and Neurosurgery, April 23-24, 2018 Rome, Italy; 24th International Conference on Neuroscience and Neurochemistry, May 24-25, 2018 Barcelona, Spain; 3rd International Conference on Spine and Spinal Disorders, June 11-12, 2018 London, UK; 25th World Congress on Neurology & Neuroscience, June 18-20, 2018 Dublin, Ireland; 7th International Conference on Addictive Disorders & Addiction Therapy, July 16-18, 2018 London, UK; 4th International Conference on Epilepsy & Treatment, August 29-30, 2018 Zurich, Switzerland; 4th World Congress on Parkinson’s & Huntington Disease, August 29-30, 2018 Zurich, Switzerland.

 

 

About Conference


ConferenceSeries Ltd welcomes every one of the members from everywhere throughout the world to go to the Dementia gathering which is held amid October 29-31, 2018 Valencia, Spain. The principle subject of our meeting is "Investigating the Challenges and Excellence in Dementia Research" which covers extensive variety of basically critical sessions. This meeting manages the ebb and flow consider improvements in the field of Dementia and about the new treatment techniques which are contrived by researchers to treat different maladies in less demanding way. This meeting goes about as a best stage for participants to find out about the current patterns in Dementia innovative work.

Dementia gathering will concentrate on the most recent and energizing developments in every aspect of Dementia consider which offers an interesting open door for agents over the globe to meet, organize, and see new logical advancements. The three days gathering incorporates workshops, symposiums and exceptional keynote sessions led by famous and eminent speakers who exceed expectations in the field of dementia This Worldwide Dementia Meeting likewise energizes the dynamic support of youthful understudies, forthcoming specialists and growing researchers as we are facilitating Poster Award Competition and Young Research Forum at the gathering setting.

Target Group of onlookers:

·         Neurologists and Executives

·         Physicians

·         Neuroscientists

·         Specialists

·         researchers

·         Health mind experts

·         Professors

·         Industrial Specialists

·         Neurosurgeons

·         Psychiatrist

·         Nutritional Researchers

·         Lecturers and Understudies from the scholarly world in the investigation of Dementia

·         Students from the scholarly community in the examination of Neurology

Alzheimer Association & Societies around the Globe

·         Alzheimer's Australia

·         Albanian Alzheimer Society

·         Association de Lucha contra el Mal de Alzheimer

·         Foundation Alzheimer Aruba (FAA)

·         Alzheimer's Australia

·         Alzheimer Austria

·         Alzheimer Support Group

·         Alzheimer Society of Bangladesh

·         Barbados Alzheimer's Association Inc.

·         Alzheimer’s and Dementia Association of The Cayman Islands

·         Ligue National Alzheimer Liga

·         Alzheimer's Family Support Group

·         Association Bolivian de Alzheimer y Otras Dementias

·         FEBRAZ - Federico Brasilia de Associaçãoes de Alzheimer

·         Corporation Alzheimer Chile

·         Alzheimer's disease Chinese

·         Alzheimer Association & Societies in Canada

 

Market Analysis

It is our pleasure to welcome you to the Dementia 2018 to be held in Valencia, Spain from October 29-31, 2018.

Dementia is general term for memory misfortune and other intellectual capacities sufficiently genuine to meddle with everyday life. Alzheimer's illness represents 60 to 80 percent of dementia cases.

This gathering will build information, offer help, help learning and enable families and carers to search out relevant administrations for their adored one and to build up the most ideal home condition to help recuperation from this mind boggling and decimating maladies.

Alzheimer's disease is the most common form of dementia. The proportions of those with different forms of dementia can be broken down as follows:

Alzheimer's disease: 62%

Vascular dementia: 17%

Mixed dementia: 10%

Lewy-body dementia: 4%

Fronto-temporal dementia: 2%

Parkinson's dementia: 2%

Other: 3%

Why Valencia??

Valencia is a city and port in Spain on the Costa Blanca, the capital of the region of Valencia and of the comarca of Valencia in the south of the Valencian People group. It is additionally a noteworthy Mediterranean port. The number of inhabitants in the city of Valencia roughly was 334,329, assessed starting at 2014, and positioning as the second-biggest Valencian city. Valencia was one of the quickest developing urban areas in Spain. The blast depended halfway on tourism coordinated to the shorelines of the Costa Blanca and especially on the second living arrangement development blast.

The general economy of the city of Valencia is arranged mostly in the program part, which connected 85.7% of the staff in the year 2007.A dozen Financial activities in Valencia did a great exchange, which customarily had the port grasp. The business exercises with the city have superb energy of bid for the greater part of the state came to by the hub related with Vinalopó to Almansa. Right now, town of Valencia positions fifth broadly in importance as far as exchange can be included, just outperformed basically by urban areas, for example, the town, Barcelona, Valencia and Seville. Alicante is home to a work area for Harmonization in the Inward Market (OHIM), European Organization for the enrollment seeing trademarks and in addition Group outlines. The real College of Alicante, in San Vicente del Raspeig, has more prominent than 33,000 understudies and pulls in an essential number of remote undergrads. The business utilizes A few.7% of the populace from the region. Features contain aluminum manufacturing plants related with snuff, Tabacalera industrial facility was for most hundreds of years of awesome monetary significance inside city.

Why to attend???

According to WHO 47.5 million people have dementia and every year 7.7 million new cases are appearing. By 2030 total cases of dementia is projected to be 75.6 million and almost triple by 2050 to 135.5 million. Alzheimer’s disease contributes 60-70 % of cases in dementia and second most common condition of dementia is vascular dementia which contributes 20% of cases all over the world. Total estimated cost of dementia is 818 billion US $ in 2015.

With members from around the world focused on learning about various Alzheimer’s disease and how to prevent the disorders. This is your best opportunity to reach the largest assemblage of participants from the entire world.

At the Dementia conferences and from the eminent people speech, you can update your knowledge about current situation of Dementia research and receive name recognition at this 3-day event. World-renowned speakers, the most recent techniques, tactics, and the newest updates in Dementia fields are hallmarks of this conference.

Conference Highlights:

Alzheimer’s disease Diagnosis and Symptoms

Managing Dementia

Care Practice and Awareness

Alzheimer’s disease Imaging

Causes and Prevention of Alzheimer’s

Alzheimer’s disease Pathophysiology and Disease Mechanisms

Amyloid Protein in Alzheimer’s and Dementia

Geriatrics Dementia and Cognitive Disorder

Therapeutic Targets and Mechanisms for Treatment

Animal Models and Translational Medicine

Alzheimer Association & Societies around the Globe:

Alzheimer's Australia

Albanian Alzheimer Society

Association de Lucha contra el Mal de Alzheimer

Foundation Alzheimer Aruba (FAA)

Alzheimer's Australia

Alzheimer Austria

Alzheimer Support Group

Alzheimer Society of Bangladesh

Barbados Alzheimer's Association Inc.

Alzheimer’s and Dementia Association of The Cayman Islands

Ligue National Alzheimer Liga

Alzheimer's Family Support Group

Association Bolivian de Alzheimer y Otras Dementias

FEBRAZ - Federico Brasilia de Associaçãoes de Alzheimer

Corporation Alzheimer Chile

Alzheimer's disease Chinese

Alzheimer Association & Societies in Canada

Products manufactured by the industries:

Three drugs are available to treat symptoms in people with Mild to moderate Alzheimer’s disease

Aricept™ produced by Pfizer Canada Inc.,

Exelon™ produced by Novartis Pharma Canada Inc.

Reminyl™ produced by Janssen Ortho Inc.

Two drugs for Moderate to advanced Alzheimer’s disease

Ebixa®

Aricept™

Past Conference Report

Dementia 2017

Past Reports  Proceedings  Gallery  

Dementia 2016

Past Reports  Proceedings  Gallery  

Dementia 2015

Past Reports  Proceedings  Gallery  

Dementia 2014

Past Reports  Gallery  

To Collaborate Scientific Professionals around the World

Conference Date October 29-31, 2018

Speaker Opportunity

Day 1 Day 2 Day 3

Supported By

Journals of Alzheimers Disease and Parkinsonism Journal of Neurological Disorders Brain Disorders and Therapy

All accepted abstracts will be published in respective Conferenceseries International Journals.

Abstracts will be provided with Digital Object Identifier by